SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report: September 30, 2005
Corgenix Medical Corporation
(Exact Name of registrant as specified in its charter)
Nevada 000-24541 93-1223466
(State or other ommission File Number) I.R.S. Employer
jurisdiction Identification No.)
of incorporation) C
12061 Tejon Street
Westminster, Colorado 80234
(Address, including zip code, of principal executive offices)
(303) 457-4345 (Registrant's telephone number
including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
? Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
? Soliciting Material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 Departure of Directors or Principal Officers; Election of
Directors; Appointment of Principal Officers
Mr. Robert Tutag was appointed to the Company's Board of Directors on September
19, 2005 to fill a vacancy created by the recent resignation of Mr. Wendell
Gardner on May 25, 2005. The Company will also recommend that Mr. Tutug be
elected by shareholders at the upcoming annual shareholders meeting tentatively
scheduled to be held on December 14, 2005. Mr. Tutag's background is described
in the attached press release which was distributed on September 20, 2005. It is
expected that Mr. Tutag will serve on the Company's Audit and Compensation
Committees. Mr. Tutag, as an outside director, will be compensated by the annual
issuance of stock options and a cash payment per board and committee meeting
attended.
ITEM 9.01 Financial Statements and Exhibits
a) Not applicable.
b) Not applicable.
c) Exhibits:
99.1 Press Release dated September 20, 2005 regarding appointment of
new board member.
Statements in this report that are not strictly historical facts are "forward
looking" statements (identified by the words "believe", "estimate", "project",
"expect" or similar expressions) within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements inherently involve risks and
uncertainties that could cause actual results to differ materially from the
forward-looking statements. Factors that would cause or contribute to such
differences include, bus are not limited to, continued acceptance of the
Company's products and services in the marketplace, competitive factors, changes
in the regulatory environment, and other risks detailed in the Company's
periodic report filings with the Securities and Exchange Commission. The
statements in this report are made as of today, based upon information currently
known to management, and the Company does not undertake any obligation to
publicly update or revise any forward-looking statements.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CORGENIX MEDICAL CORPORATION
Date: September 30, 2005 By: /s/ Douglass T. Simpson
---------------------------------
Douglass T. Simpson, President
Exhibit 99.1
CORGENIX APPOINTS VETERAN PHARMACEUTICAL EXECUTIVE TO BOARD OF DIRECTORS
New Addition to Board Brings Wealth of Experience Building Companies and
Sales Organizations within the Healthcare Industry
DENVER, COLORADO - September 20, 2005 -- Corgenix Medical Corporation (OTC BB:
CONX), a worldwide marketer of diagnostic test kits, adds significant depth of
experience to its Board by naming Robert Tutag a director of the Company. Mr.
Tutag has served since 1990 as the President of Unisource, Inc., a privately
held Boulder, Colorado company that identifies and develops niche pharmaceutical
products for generic and brand name pharmaceutical companies.
"We at Corgenix are thrilled to announce the addition of Robert Tutag to our
Board of Directors," commented Douglass T. Simpson, President and CEO of
Corgenix. "We are confident that Robert's extensive experience building sales
forces and companies in the healthcare industry will prove to be a tremendous
asset to Corgenix as we move forward in the development and marketing of our
novel diagnostic products."
Prior to joining Unisource, Mr. Tutag was President and Chief Executive Officer
of Tutag Corporation. In this role, which he fulfilled for 18 years, he
developed and managed operations of Cord Laboratories, one of the nation's
premier generic pharmaceutical manufacturing companies, in addition to founding
Geneva Generics, a generic sales and distribution company. Both Cord
Laboratories and Geneva Generics were acquired by Ciby-Geigy Corporation. During
his time with Tutag Corporation, Mr. Tutag also served as Vice President of
Sales and a Director of Tutag Pharmaceuticals, a branded distribution company.
Past experience also includes work in the banking industry, including a position
as President and Chief Executive Officer of NBR Financial, Inc., a multi-bank
holding company. Additionally, Mr. Tutag has served as editor of GMP Trends,
Inc. since 1977, an informational newsletter that reviews FDA and GMP inspection
reports for the pharmaceutical and medical device industries. Mr. Tutag received
his BBA and MBA from the University of Michigan.
About Corgenix Medical Corporation
- -------------------------------------------------------------------------------
Corgenix is a leader in the development and manufacturing of specialized
diagnostic kits for immunology disorders, vascular diseases and bone and joint
disorders. Corgenix diagnostic products are commercialized for use in clinical
laboratories throughout the world. The company currently sells over 50
diagnostic products through a global distribution network and has significant
experience advancing products through the FDA process. More information is
available at www.corgenix.com.
Company Contact:
Corgenix Medical Corp
William Critchfield, Senior VP and CFO
(303) 453-8903 Email: wcritchfield@corgenix.com
Investor Contact:
The Investor Relations Group
Kathryn McNeil / John Nesbett
Phone: (212) 825-3210
Fax: (212) 825-3229